Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis

氨基水杨酸 医学 内科学 溃疡性结肠炎 安慰剂 荟萃分析 养生 随机对照试验 胃肠病学 疾病 替代医学 病理
作者
Brigida Barberio,Jonathan Philip Segal,Mohammed Nabil Quraishi,Christopher J. Black,Edoardo Vincenzo Savarino,Alexander Charles Ford
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
卷期号:15 (7): 1184-1196 被引量:71
标识
DOI:10.1093/ecco-jcc/jjab010
摘要

BACKGROUND: 5-Aminosalicylates [5-ASAs] are the mainstay of treatment for ulcerative colitis [UC]. The optimum preparation, dose, and route of administration for UC remain unclear. We conducted a network meta-analysis to examine this issue. METHODS: We searched MEDLINE, EMBASE, EMBASE Classic, and the Cochrane central register of controlled trials from inception to December 2020. We included randomised controlled trials [RCTs] comparing oral, topical, or combined oral and topical 5-ASAs, with each other or placebo for induction of remission or prevention of relapse of UC. Results were reported as pooled relative risks [RRs] with 95% confidence intervals [CIs] to summarise effect of each comparison tested, with treatments ranked according to P-score. RESULTS: We identified 40 RCTs for induction of remission and 23 for prevention of relapse. Topical mesalazine [P-score 0.99], or oral and topical mesalazine combined [P-score 0.87] ranked first and second for clinical and endoscopic remission combined. Combined therapy ranked first in trials where ≥50% of patients had left-sided/extensive disease, and topical mesalazine first in trials where ≥50% of patients had proctitis/proctosigmoiditis. High-dose [≥3.3 g/day] oral mesalazine ranked third in most analyses, with the most trials and most patients. For relapse of disease activity, combined therapy and high-dose oral mesalazine ranked first and second, with topical mesalazine third. 5-ASAs were safe and well tolerated, regardless of regimen. CONCLUSIONS: Our results support previous evidence; however, higher doses of oral mesalazine had more evidence for induction of remission than combined therapy and were significantly more efficacious than lower doses. Future RCTs should better establish the role of combined therapy for induction of remission, as well as optimal doses of oral 5-ASAs to prevent relapse.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
kiana完成签到,获得积分10
1秒前
tengfei完成签到,获得积分10
1秒前
1秒前
bodhi完成签到,获得积分10
1秒前
寒酥完成签到 ,获得积分10
1秒前
mobei完成签到,获得积分10
1秒前
宗佳茹发布了新的文献求助10
2秒前
科研大佬的路上完成签到 ,获得积分10
2秒前
wanci的应助被LKX采纳,获得10
2秒前
高挑的葵阴完成签到,获得积分10
2秒前
xh完成签到 ,获得积分10
2秒前
ljy0825完成签到 ,获得积分10
2秒前
Orange的应助被quhayley采纳,获得10
2秒前
无声瀑布完成签到,获得积分10
3秒前
稀饭完成签到,获得积分10
3秒前
3秒前
null的应助被科研通管家采纳,获得10
3秒前
3秒前
邓力的应助被科研通管家采纳,获得10
3秒前
树池完成签到,获得积分10
3秒前
邓力的应助被科研通管家采纳,获得10
3秒前
情怀的应助被科研通管家采纳,获得30
4秒前
爆米花的应助被biotech_soldier采纳,获得10
4秒前
完美世界的应助被科研通管家采纳,获得10
4秒前
丘比特的应助被科研通管家采纳,获得10
4秒前
null的应助被科研通管家采纳,获得10
4秒前
略略略完成签到,获得积分0
4秒前
派大星完成签到,获得积分10
5秒前
5秒前
清爽盼秋发布了新的文献求助10
5秒前
beichen完成签到,获得积分10
6秒前
俊鱼完成签到,获得积分10
6秒前
ok123完成签到 ,获得积分10
6秒前
Sara_123完成签到,获得积分10
6秒前
张思哲完成签到,获得积分10
6秒前
李琪完成签到 ,获得积分10
8秒前
palette完成签到,获得积分10
8秒前
8秒前
落雁完成签到 ,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159288
求助须知:如何正确求助?哪些是违规求助? 9554702
关于积分的说明 21720900
捐赠科研通 7748911
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552111
邀请新用户注册赠送积分活动 2471479